Asset Details
Do you wish to reserve the book?
Depression: Managing Resistance and Partial Response to Treatment
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Depression: Managing Resistance and Partial Response to Treatment
Do you wish to request the book?
Depression: Managing Resistance and Partial Response to Treatment
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Depression: Managing Resistance and Partial Response to Treatment
2024
Overview
Treatment-resistant depression is defined as absence of remission despite trials of two or more antidepressant medications and can occur in up to 31% of patients with major depressive disorder. Partial response to treatment is defined as less than 50% reduction in depression-rating scores. Before diagnosing treatment-resistant depression or partial response to treatment, adherence to adequate doses and duration of medications should be confirmed. Management strategies include adding psychotherapy, switching antidepressant medication class, or augmenting with additional medications. Current guidelines recommend augmentation with a second-generation antidepressant, an atypical antipsychotic, tricyclic antidepressants, lithium, or a triiodothyronine medication as pharmacologic options. Ketamine and esketamine can also be used as augmentation for treatment-resistant depression and may help reduce suicidal ideation. Electroconvulsive therapy and repetitive transcranial magnetic stimulation may be effective. Pharmacogenetic testing has limited evidence and is not recommended. Nonpharmacologic therapies include psychotherapy, exercise, and focused dietary changes.
Publisher
American Academy of Family Physicians
Subject
/ Antidepressive Agents - therapeutic use
/ Depressive Disorder, Major - drug therapy
/ Depressive Disorder, Major - therapy
/ Depressive Disorder, Treatment-Resistant - diagnosis
/ Depressive Disorder, Treatment-Resistant - drug therapy
/ Depressive Disorder, Treatment-Resistant - therapy
/ Electroconvulsive Therapy - methods
/ Family Medicine/General Medicine
/ Humans
